Tag:

Eli Lilly

Latest Headlines

Latest Headlines

UPDATED: Eli Lilly scraps tabalumab for lupus after it flops in (another) PhIII program

Eli Lilly's tabalumab has flopped in another Phase III program, failing to score well enough to survive as a potential new treatment for lupus--a follow-up setback to its earlier failure in rheumatoid arthritis. Lilly now plans to bury the program in its crowded graveyard of late-stage drugs.

Elanco and Dow AgroSciences team up to meet global demand for food

Elanco, the animal health division of Eli Lilly, and Dow AgroSciences said they are partnering to jointly focus on helping producers increase meat and milk production to meet a growing global demand. 

EU panel backs slew of new drugs and uses, boosting Lilly, AZ, Novartis, Gilead and more

When Europe's drug approval gatekeepers meet, they often tick off recommendations for some key Big Pharma products. This week, the Committee for Medicinal Products for Human Use backed a whopping 15 new meds and 3 new indications.

UPDATED: FDA hands Eli Lilly a big win, OKs dulaglutide for diabetes

An embattled Eli Lilly won a major battle today, gaining the FDA's approval to market dulaglutide for Type 2 diabetes. It will be sold as Trulicity.

Put a lid on 'Low-T' drug use, FDA panel advises, threatening AbbVie, Lilly meds

An FDA advisory panel wants to limit the use of testosterone drugs for safety reasons--and the proposed restrictions would shrink sales significantly. That's not good news for AbbVie, the market leader, and other drugmakers that have been riding a surge of testosterone growth.

Eli Lilly takes the lead on AstraZeneca's Alzheimer's drug in $500M deal

Longtime Alzheimer's player Eli Lilly has agreed to pay $50 million in a near-term milestone and take charge of the development work in a collaboration package worth a total of up to $500 million.

Lilly says with new data, it will seek another approval for Cyramza next year

Eli Lilly has harbored big hopes for its newly approved cancer fighter Cyramza. It expects it to get a string approvals, and with new data in hand, it said it will go to the FDA with an application for colon cancer in the first half of next year.

As America's diabetes problem grows, so do prices on Lilly's Humulin

Since 2007, the wholesale cost for a one-month supply of insulin product Humulin has gone from about $220 to approximately $1,200, MedPage Today reports.

Cyramza, key to Lilly's oncology hopes, comes through in colorectal cancer

Eli Lilly's Cyramza (ramucirumab) met its primary endpoint in a study on metastatic colorectal cancer, good news for a key cog in the drugmaker's plans to capitalize on oncology.

Lilly and Boehringer snag EU nod for Lantus knockoff, but stateside hopes stay on ice

Eli Lilly and Boehringer Ingelheim won European clearance for their biosimilar of Lantus, Sanofi's top-selling insulin product, but the treatment's full potential remains hamstrung by a U.S. patent challenge.